Supreme Court to Myriad Genetics: Synthetic DNA is Patentable but Isolated Genes Are Not

Weinmeyer, Richard; Klusty, Tobin

doi:10.1001/journalofethics.2015.17.9.hlaw1-1509

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2018

2024

Publication Types

Select...

Article3

Book1

Relationship

Self Cite0

Independent4

Authors

Journals

Cited by 4 publications

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Proprietary strategies in precision medicine

Wan,

Silva,

Odenweller

et al. 2024

Comprehensive Precision Medicine

View full text Add to dashboard Cite

Proprietary strategies in precision medicine

Wan,

Silva,

Odenweller

et al. 2024

Comprehensive Precision Medicine

View full text Add to dashboard Cite

Therapeutic implications of germline vulnerabilities in DNA repair for precision oncology

Shah

Demidova

Lesh

et al. 2022

Cancer Treatment Reviews

View full text Add to dashboard Cite

DNA repair vulnerabilities are present in a significant proportion of cancers. Specifically, germline alterations in DNA repair not only increase cancer risk but are associated with treatment response and clinical outcomes. The therapeutic landscape of cancer has rapidly evolved with the FDA approval of therapies that specifically target DNA repair vulnerabilities. The clinical success of synthetic lethality between BRCA deficiency and poly(ADPribose) polymerase (PARP) inhibition has been truly revolutionary. Defective mismatch repair has been validated as a predictor of response to immune checkpoint blockade associated with durable responses and long-term benefit in many cancer patients. Advances in next generation sequencing technologies and their decreasing cost have supported increased genetic profiling of tumors coupled with germline testing of cancer risk genes in patients. The clinical adoption of panel testing for germline assessment in high-risk individuals has generated a plethora of genetic data, particularly on DNA repair genes. Here, we highlight the therapeutic relevance of germline aberrations in DNA repair to identify patients eligible for precision treatments such as PARP inhibitors (PARPis), immune checkpoint blockade, chemotherapy, radiation therapy and combined treatment. We also discuss emerging mechanisms that regulate DNA repair.

show abstract

The latest trends in peptide drug discovery and future challenges

Otvos

2024

Expert Opinion on Drug Discovery

View full text Add to dashboard Cite

Supreme Court to Myriad Genetics: Synthetic DNA is Patentable but Isolated Genes Are Not

Cited by 4 publications

References 2 publications

Proprietary strategies in precision medicine

Proprietary strategies in precision medicine

Therapeutic implications of germline vulnerabilities in DNA repair for precision oncology

The latest trends in peptide drug discovery and future challenges

Contact Info

Product

Resources

About